Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06996951 · ClinicalTrials.gov registry record · Phase 3

Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy

A Phase 3 study of Cystic Fibrosis (CF) and Chronic Rhinosinusitis (CRS), sponsored by Indiana University.

Recruiting
Registry status
Phase 3
Development phase
64
Enrollment target
1
Study location

NCT06996951: Recruiting Phase 3 study of Cystic Fibrosis (CF) and Chronic Rhinosinusitis (CRS), sponsored by Indiana University.

NCT06996951 is a Phase 3 study of Cystic Fibrosis (CF) and Chronic Rhinosinusitis (CRS) that is actively recruiting participants, run by Indiana University. The registered enrollment target is 64 participants, below the 136-participant average among 14 other Cystic Fibrosis (CF) trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06996951, a Phase 3 study of Cystic Fibrosis (CF) and Chronic Rhinosinusitis (CRS), is actively recruiting participants, sponsored by Indiana University.

RECRUITING
Registry status
Phase 3
Development phase
64 participants
Enrollment target
1
Study location

Study Summary

The investigators are doing this study to discover if it is appropriate for people with Cystic Fibrosis (CF) on highly effective modulator therapy (HEMT) to stop using certain standard Sino nasal therapies such as high-volume nasal saline irrigations, topical nasal steroids, and topical nasal antibiotics. They are also going to study the fluid inside the nose to see if there are changes when stopping these therapies. Right now, they are not sure if it is suggested to stop these treatments when patients begin highly effective modulator therapy (HEMT)

Primary Outcome

Nasal Endoscopy will be performed in the clinic to evaluate the sinonasal cavities using the Lund Kennedy scoring system. The Lund-Kennedy endoscopic score grades the severity of chronic rhinosinusitis (CRS) based on findings from five areas: polyps, discharge, edema, scarring, and crusting, with each graded on a scale of 0 to 2 for each nostril, resulting in a total possible score of 20. A higher score indicates more severe disease.

Interventions

  • OTHER STOP NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID
  • DRUG CONTINUE NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID

Study Locations (1)

Indiana

  • Indiana University Health - Indianapolis

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2025-07-02
Est. Completion 2026-07
Phase Phase 3
Indiana University

890 total trials

What NCT06996951 shows while recruiting

NCT06996951 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 136-participant average among 14 other Cystic Fibrosis (CF) trials with a reported enrollment target (53% lower).

The record links to 2 conditions, with Cystic Fibrosis (CF) appearing as the primary indexed condition, and to 2 interventions - of which STOP NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID is the first listed.

NCT06996951 reports a single indexed study location in Indiana.

Frequently Asked Questions

What is clinical trial NCT06996951 about?

NCT06996951 is a clinical study titled "Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy". The investigators are doing this study to discover if it is appropriate for people with Cystic Fibrosis (CF) on highly effective modulator therapy (HEMT) to stop using certain standard Sino nasal therapies such as high-volume nasal saline irrigations, topical nasal steroids, and topical nasal antibi...

What is the current status of trial NCT06996951?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 64 participants. The study started on 2025-07-02. Estimated completion is 2026-07.

What conditions does trial NCT06996951 study?

This clinical trial studies the following conditions: Cystic Fibrosis (CF), Chronic Rhinosinusitis (CRS).

What interventions are being tested in trial NCT06996951?

The interventions under investigation include: STOP NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID (OTHER), CONTINUE NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID (DRUG).

Who is sponsoring clinical trial NCT06996951?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06996951 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cystic Fibrosis (CF)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06996951's enrollment target sits among peer trials

64 9th of 14 higher than 6 of 14 other Cystic Fibrosis (CF) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cystic Fibrosis (CF) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01853631 · 64 participants · Phase 1

    Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

  • NCT03739502 · 64 participants · Phase 2

    A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

  • NCT03739814 · 64 participants · Phase 2

    Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • NCT03866408 · 64 participants · Early Phase 1

    Insulin Regulation of Lipolysis and Lipolysis Proteins

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06996951, the US trial registry maintained by the National Library of Medicine. NCT06996951 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.